CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 161 enrolled
Drug / intervention
Tamsulosin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04859660
NCT04859660Phase 2Completed
CompareCT.gov

Pre-operative Tamsulosin After Minimally Invasive Hysterectomy and Time to Spontaneous Void: A Randomized Controlled Trial

University of Arizona·interventional·Posted Apr 26, 2021·Updated Feb 29, 2024

In Brief

A Phase 2 clinical trial evaluating Tamsulosin and Placebo for Urinary Retention Postoperative. Completed, enrolled 161 participants across 2 sites.

Detailed Summary

The aim of this study is to determine if a one time dose of tamsulosin given pre-operatively decreases the time to void and the time to discharge after minimally invasive hysterectomy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUrinary Retention Postoperative
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedApr 26, 2021
Enrollment StartApr 16, 2021
Primary CompletionJun 24, 2023
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 5.2 years ago

Interventions

Tamsulosindrug

Participants will be given Tamsulosin or placebo in the pre-op bay prior to surgery. Post-operatively, time to void and time to discharge from the post-anesthesia care unit will be recorded.

Placebodrug

Participants will be given Tamsulosin or placebo in the pre-op bay prior to surgery. Post-operatively, time to void and time to discharge from the post-anesthesia care unit will be recorded.